论文部分内容阅读
新型抗凝药利伐沙班在非瓣膜性心房颤动患者预防脑卒中或全身性栓塞已有充分的临床应用证据，但其在心房颤动导管消融围手术期的用药策略尚无统一意见。通过对相关临床研究进行分类分析，以期为利伐沙班在心房颤动导管消融围手术期的临床合理应用策略提供参考。“,”Rivaroxaban was approved for the prevention of stroke or embolism in patients with nonvalvular atrial fibrillation ( AF ) . However, There is no unified opinion of periprocedural anticoagulation strategies for the patients undergoing AF ablation.This article reviews the studies of periprocedural management of rivaroxaban in patients undergoing AF ablation,to provide evidence for clinical reasonable appli-cation strategy of rivaroxaban.